癌症中的NRF2激活和NRF2小分子抑制剂的概述
Hoang Hai Ngo1, Bo-Yeong Yu1, Jeong-Eun Lee1
1College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University, 32 Dongguk-Ro, Goyang, 10326, Gyeonggi-Do, Korea.
Archives of pharmacal research
|August 15, 2025
概括
核因子红色素2相关因子2 (NRF2) 通常保护细胞,但在突变时驱动癌症化学抵抗. 本综述探讨了NRF2调节,它在化学抵抗中的作用,以及针对NRF2成癌细胞的治疗策略.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
背景情况:
- 核因子红色素2相关因子2 (NRF2) 是一种转录因子,对抗氧化和排毒反应至关重要.
- 虽然植物化学物质的NRF2激活在正常细胞中具有保护作用,但其在癌症中的异常激活促进了瘤生长和化学抵抗.
- 在KEAP1/NRF2路径的突变驱动瘤性NRF2活动,创造了一个亲瘤的微环境.
研究的目的:
- 阐明管理NRF2.2的监管机制.
- 讨论NRF2激活在赋予癌细胞化学抗性的作用.
- 探索针对依赖NRF2.2的癌细胞的治疗策略.
主要方法:
- 对有关NRF2调节和癌症功能的现有文献的综述.
- 分析NRF2介导化学阻力背后的分子机制.
- 检查治疗方法,包括小分子NRF2抑制剂.
主要成果:
- NRF2 调节了超出氧化还原平衡的多种细胞过程,包括新陈代谢和蛋白质平衡.
- 癌症中异常的NRF2激活有助于癌症的扩散,生存和抗化学疗法.
- 正在开发针对NRF2依赖癌症脆弱性的特定治疗策略.
结论:
- 了解NRF2调节是解读其在癌症中的双重作用的关键.
- 准NRF2为克服癌症化学抵抗提供了一个有希望的途径.
- 小分子NRF2抑制剂代表了对NRF2成癌症的潜在治疗策略.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.6K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.6K
NF-κB-dependent Signaling Pathway
7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.8K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


